Prescott Group Capital Management, L.L.C. Vertex Pharmaceuticals Inc Transaction History
Prescott Group Capital Management, L.L.C.
- $615 Million
- Q1 2025
A detailed history of Prescott Group Capital Management, L.L.C. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Prescott Group Capital Management, L.L.C. holds 597 shares of VRTX stock, worth $266,548. This represents 0.05% of its overall portfolio holdings.
Number of Shares
597Holding current value
$266,548% of portfolio
0.05%Shares
3 transactions
Others Institutions Holding VRTX
# of Institutions
1,832Shares Held
233MCall Options Held
1.38MPut Options Held
1.08M-
Capital World Investors Los Angeles, CA28.5MShares$12.7 Billion2.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.5MShares$10.5 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.52 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA14.5MShares$6.49 Billion1.6% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.26 Billion0.24% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $115B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...